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Over all, this study is well done; however, a strong conclusion
will not be drawn given the lack of rigid dietary control and a small
number of studied subjects. Due to the latter circumstances, the
lack of signiﬁcant increase in urinary citrate despite a signiﬁcant
rise in urinary pH, and a signiﬁcant fall in urinary ammonium with
LithoLyte, and conversely, the effect of KSPtabs in a signiﬁcant rise
in urinary citrate and urinary pH without a signiﬁcant fall in urinary
ammonium could not be fully explained.
The heterogeneous biochemical response with these 2 alkali
preparations to a major extent is due to different amount of alkali
delivered by 2 products. The alkali delivered by the 2 preparations differed by 9.5 mEq/day. Therefore, this difference in addition to lack of dietary control and a small sample size, have
greatly affected the result and requires to be fully investigated in
the future. Moreover, urinary potassium with both LithoLyte and
KSPtabs, did not change signiﬁcantly suggestive of either lack of
compliance to the drug or due to diarrhea loss of potassium.
With regard to the side effects, both these preparations as well
as previous studies in recurrent calcium oxalate stone formers by
Ettinger et al. 2 and by Barcelo, et al in hypocitraturic calcium
stone former, 3 showed similar minor gastrointestinal side effects
including mild nausea, epigastric pain or abdominal distension.
Although the dosage of alkali used in Ettinger and Barcelo studies
was higher than this study 1 using 63 mEq/day of potassium magnesium citrate and 45 mEq/day potassium citrate, respectively.
Thereby, no deﬁnitive conclusion can be made with the present
study that LithoLyte and KSPtabs supplements would offer a
more protective role with the gastrointestinal adverse effects.
It must be acknowledged that this is the ﬁrst step toward the
development of over-the-counter alkali therapy for the kidney
stone formation concerning side effects, tolerability, and cost.
However, due to the deﬁciency in the design comprehensive
studies under metabolic regimen using these alternative overthe-counter alkali supplements, must be performed in kidney
stone forming population to overcome the limitation of this
study. I feel until that time the AUA guidelines 4 recommended
potassium citrate as the primary alkali therapy for kidney stone
formers must be followed by urologists and nephrologists
involved in management and care of this population.
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References
1. Canvasser N. Editorial Comment. Over-the-counter alkali agents to
raise urine pH and citrate excretion: a prospective crossover study in
healthy adults. 2022.
2. Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel
A. Potassium- magnesium citrate is an effective prophylaxis against
recurrent calcium oxalate nephrolithiasis. J Urol. 1997;158:2069–
2073. https://doi.org/10.1016/s0022-5347(01)68155-2.
3. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized
double-blind study of potassium citrate in idiopathic hypocitraturic
calcium nephrolithiasis. J Urol. 1993;150:1761–1764.
4. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of
kidney stones: AUA guideline. J Urol. 2014;192:316–324. https://doi.
org/10.1016/j.juro.2014.05.006.

https://doi.org/10.1016/j.urology.2022.05.050
UROLOGY 168: 76−77, 2022. © 2022 Elsevier Inc.

Author Reply
Reply by authors:

We appreciate the thoughtful critique of this manuscript by the
author of the editorial. The purpose of this study was not to
show that these over-the-counter alternatives are as effective as
potassium citrate; we did not have a control group on potassium
citrate. Rather, we tested whether these commonly used alkali
supplements actually change urine parameters in healthy subjects.
Online shopping has empowered patients to look for alternative therapies due to potassium citrate cost, side effects, pill size,
and/or desire for a “natural” approach. While dozens of options
exist, the endourology community needs to study these therapies
so that patients are able to choose effective options based on science, not star ratings and online reviews.
Studying alkali alternatives in a small sample size is not novel.
Twelve patients were given 2L of lemonade with signiﬁcant
improvements in urine citrate,1 which continues to be 1 of the
most common adjunctive therapies used. Thirteen subjects on a
metabolic diet were studied to show that orange juice is a superior alkali compared to lemonade.2 And 8 patients demonstrated
the beneﬁt of coconut water consumption due to the alkali effect
of high malate intake.3 Certainly, our 10-subject study with varied alkali loads between supplements on self-controlled diets is a
limitation. While we were not directly comparing 1 supplement
to the other, we chose to maintain a similar dosing frequency for
consistency despite the alkali loads. In addition, given the lower
potassium citrate content of these preparations compared to
pure potassium citrate, we might not see a robust urinary potassium response. Any patient started on alkali therapy should be
monitored with 24 hour urine studies to ensure efﬁcacy. We will
further study 24 hour urine parameters in an at-risk study population.
We are indebted to Dr. Sakhaee et al. at the Charles and Jane
Pak Center for Mineral Metabolism and Clinical Research at
UT Southwestern, whose work on nephrolithiasis pathophysiology and prevention is the foundation for much of what we do.
Products continue to be developed for kidney stone prevention,
many within our own community. As stewards of preventative
therapy, we need to study and be critical of these options in
order to better guide our patients.
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